Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines
Abstract Waning immunity after two SARS-CoV-2 mRNA vaccinations and the emergence of variants precipitated the need for booster doses. We evaluated safety and serological and cellular immunogenicity through 6 months after a third mRNA vaccination in adults who received the mRNA-1273 primary series in the Phase 1 trial approximately 9 to 10 months earlier. The booster vaccine formulations included 100 mcg of mRNA-1273, 50 mcg of mRNA-1273.351 that encodes Beta variant spike protein, and bivalent vaccine of 25 mcg each of mRNA-1273 and mRNA-1273.351. A third dose of mRNA vaccine appeared safe with acceptable reactogenicity. Vaccination induced rapid increases in binding and neutralizing antibody titers to D614G, Beta, Delta and Omicron variants that persisted through 6 months post-boost, particularly after administration of Beta-containing vaccines. Spike-specific CD4 + and CD8 + T cells increased to levels similar to those following the second dose. Boost vaccination induced broad and durable humoral and T cell responses. ClinicalTrials.gov numbers NCT04283461 (mRNA-1273 Phase 1) and NCT04785144 (mRNA-1273.351 Phase 1).
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 26. Apr. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-1594631/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA035850337 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA035850337 | ||
| 003 | DE-627 | ||
| 005 | 20230429185720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220427s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1594631/v1 |2 doi | |
| 035 | |a (DE-627)XRA035850337 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1594631/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Anderson, Evan J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Waning immunity after two SARS-CoV-2 mRNA vaccinations and the emergence of variants precipitated the need for booster doses. We evaluated safety and serological and cellular immunogenicity through 6 months after a third mRNA vaccination in adults who received the mRNA-1273 primary series in the Phase 1 trial approximately 9 to 10 months earlier. The booster vaccine formulations included 100 mcg of mRNA-1273, 50 mcg of mRNA-1273.351 that encodes Beta variant spike protein, and bivalent vaccine of 25 mcg each of mRNA-1273 and mRNA-1273.351. A third dose of mRNA vaccine appeared safe with acceptable reactogenicity. Vaccination induced rapid increases in binding and neutralizing antibody titers to D614G, Beta, Delta and Omicron variants that persisted through 6 months post-boost, particularly after administration of Beta-containing vaccines. Spike-specific CD4 + and CD8 + T cells increased to levels similar to those following the second dose. Boost vaccination induced broad and durable humoral and T cell responses. ClinicalTrials.gov numbers NCT04283461 (mRNA-1273 Phase 1) and NCT04785144 (mRNA-1273.351 Phase 1) | ||
| 700 | 1 | |a Jackson, Lisa A. |e verfasserin |4 aut | |
| 700 | 1 | |a Rouphael, Nadine G. |e verfasserin |4 aut | |
| 700 | 1 | |a Widge, Alicia T. |e verfasserin |4 aut | |
| 700 | 1 | |a Montefiori, David |e verfasserin |4 aut | |
| 700 | 1 | |a Doria-Rose, Nicole A. |e verfasserin |4 aut | |
| 700 | 1 | |a Suthar, Mehul |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Kristen W. |e verfasserin |4 aut | |
| 700 | 1 | |a O’Connell, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Makowski, Mat |e verfasserin |4 aut | |
| 700 | 1 | |a Makhene, Mamodikoe |e verfasserin |4 aut | |
| 700 | 1 | |a Buchanan, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Spearman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Creech, C. Buddy |e verfasserin |4 aut | |
| 700 | 1 | |a O’Dell, Sijy |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Stephen D |e verfasserin |4 aut | |
| 700 | 1 | |a Leav, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Bennett, Hamilton |e verfasserin |4 aut | |
| 700 | 1 | |a Pajon, Rolando |e verfasserin |4 aut | |
| 700 | 1 | |a Posavad, Christine M. |e verfasserin |4 aut | |
| 700 | 1 | |a Hural, John |e verfasserin |4 aut | |
| 700 | 1 | |a Beigel, John H. |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, Jim |e verfasserin |4 aut | |
| 700 | 1 | |a Abebe, Kuleni |e verfasserin |4 aut | |
| 700 | 1 | |a Eaton, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Rostad, Christina A. |e verfasserin |4 aut | |
| 700 | 1 | |a Rebolledo, Paulina A. |e verfasserin |4 aut | |
| 700 | 1 | |a Kamidani, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Graciaa, Daniel S. |e verfasserin |4 aut | |
| 700 | 1 | |a Coler, Rhea |e verfasserin |4 aut | |
| 700 | 1 | |a McDermott, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Ledgerwood, Julie E. |e verfasserin |4 aut | |
| 700 | 1 | |a Mascola, John R. |e verfasserin |4 aut | |
| 700 | 1 | |a De Rosa, Stephen C. |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M. |e verfasserin |4 aut | |
| 700 | 1 | |a McElrath, M. Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Paul C. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 26. Apr. |
| 773 | 1 | 8 | |g year:2022 |g day:26 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1594631/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 26 |c 04 | ||
| 953 | |2 045F |a 570 | ||